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Abstract: Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is
usually characterized by a self-limited course. However, there is an increased risk of HEV persistence
in immunocompromised risk populations, comprising patients following solid organ transplantation
or hematological malignancies. Recently, chronic HEV infection following rituximab-containing
treatment regimens has been described. Here we report five patients with chronic hepatitis E after
prior rituximab therapy for various indications. We determined the immunological characteristics of
these patients and analyzed the development of ribavirin (RBV) treatment failure-associated mutations
in the HEV genome. One patient became chronically HEV-infected 110 months after administration
of rituximab (RTX). Immunological characterization revealed that all patients exhibited significant
hypogammaglobulinemia and CD4+ T cell lymphopenia. One patient permanently cleared HEV
following weight-based ribavirin treatment while three patients failed to reach a sustained virological
response. In depth mutational analysis confirmed the presence of specific mutations associated
with RBV treatment failure in these patients. Our cases indicate that rituximab-containing treatment
regimens might imply a relevant risk for persistent HEV infection even years after the last rituximab
application. Moreover, we provide further evidence to prior observations suggesting that chronically
HEV infected patients following RTX-containing treatment regimens might be difficult to treat.
Keywords: hepatitis E; rituximab; ribavirin resistance; hypogammaglobulinemia: CD4+ T cell
lymphopenia
1. Introduction
Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is
usually asymptomatic and self-limiting [1]. Patients who fail to clear HEV three months after the
onset of infection are defined as persistently infected, and weight-based ribavirin (RBV) treatment
is recommended as standard first-line therapy in these patients [2]. Effective second-line treatment
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options in patients who fail to achieve sustained virological response (SVR) following RBV first-line
therapy appear to be limited and comprise prolonged RBV retreatment periods or pegylated interferon.
We and others have demonstrated that the potent hepatitis C polymerase inhibitor sofosbuvir, which
showed anti-HEV effects in vitro [3], appears to be an ineffective rescue therapy in these difficult-to-treat
patients [4]. Moreover, these patients are at risk of an aggressive course of their chronic HEV infection
with rapid progression to end-stage liver cirrhosis [5].
There is an increased risk of HEV persistence in patient populations under immunosuppression
after solid organ transplantation receiving calcineurin inhibitors, corticosteroids, mycophenolic acid,
cyclosporine A, or mammalian target of rapamycin (mTOR) inhibitors, often administered as combined
drug therapy [6–8], and in patients with hematological malignancies [9]. Persistent hepatitis E has
also been described in patients with idiopathic CD4+ T lymphopenia and human immunodeficiency
virus (HIV) infection with low CD4+ T-cell counts [10,11]. Diagnosis of chronic HEV infection in these
risk populations is usually based on PCR since the humoral response resulting in anti-HEV antibodies
immunoglobulin M/G (IgM/IgG) is often delayed or even absent. Anecdotal cases of persistent HEV
infection during or following different treatment regimens involving rituximab (RTX) have been
described recently with mixed response rates to standard RBV or interferon treatment as depicted in
supplementary Table S1 [9,12–17]. RTX is a monoclonal CD20 antibody that leads to B-cell depletion
for an extended period. Beside hepatotoxicity, reactivation of viral infections, especially hepatitis B
virus, is a relevant and potentially life-threatening side effect of RTX-containing treatment regimens.
Therefore, current hepatitis B clinical practice guidelines recommend hepatitis B testing in all patients
undergoing RTX treatment to avoid fulminant hepatitis B reactivation [18].
Here we examined five patients with chronic hepatitis E following prior RTX therapy for various
underlying diseases. We also determined the immunological characteristics of these patients and
analyzed the development of previously described mutations in the HEV genome, which might affect
the outcome of ribavirin treatment [19–25].
2. Materials and Methods
Mutational Analyses of the HEV Polymerase region.
Viral RNA was extracted from EDTA-plasma using the QIAamp Viral RNA mini Kit (Qiagen,
Hilden, Germany) and the QIAcube (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. RNA was reverse transcribed into cDNA with SuperScript IV Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA) per manufacturer’s recommendations except with a prolonged
incubation step of 20 min at 50 ◦C and 15 min at 55 ◦C. Semi-nested PCR for amplification of the
RNA-dependent RNA-polymerase (RdRp)-gene of the HEV genome was performed using the Phusion
Hot Start II High-Fidelity DNA Polymerase (Thermo Fisher Scientific, Waltham, MA, USA). Sense
primer HEV-247_f and antisense primer HEV-128_r were used for the first PCR. Sense primer HEV-247_f
and antisense primer HEV-248_r were used for the second PCR (Table 1). PCR conditions were: 30 s
at 98 ◦C and 35 cycles consisting of 5 s at 98 ◦C, 30 s at 61 ◦C, 1 min at 72 ◦C, followed by 2 min at
72 ◦C. Amplicons were sequenced using the primers HEV-27, HEV-38, HEV-39, HEV-165, HEV-166,
and HEV-247 with the BigDye Terminator (version 3.1) cycle sequencing kit (Applied Biosystems,
Waltham, MA, USA) and the Applied Biosystems 3500 Dx Series Genetic Analyzer (Thermo Fisher
Scientific, Waltham, MA, USA) (Table 1).
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Table 1. Primers used for amplification of the RNA-dependent RNA-polymerase (RdRp) region and
sequencing. HEV: hepatitis E virus.









Resulting sequences were analyzed using the software Geneious 11.1.5 (Biomatters, Auckland,
New Zealand). The sequences were analyzed regarding the previously reported seven mutations in
the HEV-Polymerase region possibly associated with RBV treatment failure [19–25]. For genotyping
the HEV Genotyping Tool https://www.rivm.nl/mpf/typingtool/hev/ (RIVM—Netherlands National




A 69-year old male received seven cycles of R-CHOP plus two cycles of RTX in 2008 and 2009 for
non-Hodgkin’s, lymphoma leading to long-term remission. A regular follow-up examination in July
2016 revealed elevated aminotransferases indicating hepatitis. An extended laboratory examination
including HEV serology without HEV RNA testing failed to unravel the underlying cause. A liver
biopsy obtained in September 2016 exhibited histological features of viral hepatitis, but laboratory
results remained negative for hepatotropic viruses. The patient remained undiagnosed until HEV
RNA quantitation was performed in March 2018, revealing a HEV load of 4.15 E6 copies/mL despite
persistent HEV seronegativity until present (recomWell HEV IgG/IgM and for confirmation recomLine
HEV IgG/IgM, both Mikrogen Neuried, Germany). Weight-based RBV was administered at a dose of
1000 mg/day for three months and the patient cleared HEV, which led to the termination of therapy.
HEV relapsed after 4 weeks and RBV treatment was re-induced at a dose of 1000 mg/d for 4 additional
months without achieving viral clearance. After a treatment pause of two months RBV was continued
at a reduced dose of 800 mg/d due to increasing fatigue and insomnia of the patient, who shows
persisting HEV replication and constantly elevated aminotransferases until present.
3.1.2. Case 2
A 64-year old male with elevated aminotransferases presented himself at our outpatient clinic. He
had been diagnosed with a monoclonal gammopathy of undetermined significance in 1992. In 2012, he
had received eight cycles of bendamustine and RTX for Waldenstrom macroglobulinemia. Due to a
relapse in 2016 he had been retreated with six cycles of bendamustine and RTX until February 2017,
with stable remission since then. In November 2017, elevated aminotransferases were noted for the
first time and the patient reported a short period of jaundice and fatigue. Extended laboratory testing
revealed a HEV load of 6.1 E7 copies/mL. HEV IgG was positive and HEV IgM negative. After three
months of persistent HEV replication, weight-based RBV treatment was started at a dose of 800 mg/d
leading to virus clearance after three months of RBV treatment. RBV was stopped, but HEV relapsed
only one month later and the patient was retreated with 800 mg RBV/d for an additional three months,
achieving a sustained virological response.
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3.1.3. Case 3
A 22-year old male patient had been treated with eculizumab from 2013 to 2015 for two years
followed by RTX due to an atypical hemolytic-uremic syndrome and immune thrombocytopenia.
RTX was administered from May to June 2015 (three cycles). In the following years, the patient
suffered from recurrent infections including several episodes of bacterial bloodstream infections.
A severe immunoglobulin deficiency was diagnosed and the patient was treated with intravenous
immunoglobulin G substitutions. The patient also received long-term treatment with corticosteroids.
Elevated aminotransferases were noticed from the end of 2015. In September 2017, he was admitted to
our intensive care unit with a septic shock caused by an abscess in the left axilla. During recovery from
the sepsis, jaundice was noticed and HEV RNA was detected in his blood (413 mio copies/mL) and
feces. RBV therapy was initiated at a reduced dose of 200 mg/d due to his impaired renal function and
was subsequently reduced to 200 mg three times per week. In the further course, RBV treatment was
increased to a dose of 200–400 mg/d but had to be terminated after 4.5 months due to severe anemia
and leukopenia. HEV replication remained continuously detectable throughout the complete RBV
treatment period, confirming non-response in this patient.
3.1.4. Case 4
A 68-year old male patient had been diagnosed with marginal zone lymphoma in 2011. He had
received chemotherapy (R-CHOP) and autologous hematopoietic stem cell transplantation in 2012.
After recurrence of his lymphoma in 2015 he had been treated with ibrutinib from 2015 to 2017 followed
by bendamustine and RTX from January to October 2018. He had increased aminotransferases in
March 2019, and HEV RNA was measured at 43 mio copies/mL in June 2019, prompting the initiation
of treatment with ribavirin at a dose of 600 mg/d, which led to HEV clearance in July 2019. RBV
treatment was terminated and the patient showed no HEV replication in October 2019. In November
2019, a viral relapse was detected and retreatment with 600 mg RBV/d was initiated.
3.1.5. Case 5
A 31-year old male patient underwent kidney transplantation due to hypoplastic kidneys in
1997. He developed a severe post-transplant lymphoma (PTLD) requiring chemotherapy (five cycles
of RTX and high-dose cytarabine followed by another cycle of RTX monotherapy) in April 2013. In
2015, he experienced terminal renal graft failure leading to the discontinuation of post-transplant
immunosuppression consisting of corticosteroids and mycophenolate mofetil. He suffered from
immunoglobin deficiency treated with intravenous immunoglobin G substitutions. In May 2019, an
abdominal ultrasound revealed a compensated liver cirrhosis. Extended laboratory testing revealed
HEV infection which was also detectable in retained blood samples, confirming the diagnosis of a
chronic hepatitis E. RBV treatment was initiated (dose of 200 mg/d), but had to be discontinued shortly
after due to severe thrombocytopenia and the reduced general condition of the patient.
Table 2 summarizes the underlying disease, immunosuppressive medication, time from last
administration of RTX to HEV diagnosis, laboratory results, and HEV serology at the time of HEV
diagnosis of the present patient cohort.
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Table 2. Underlying disease, immunosuppressive medication, time from last administration of rituximab (RTX) to HEV diagnosis, laboratory results, and HEV
serology at the time of HEV diagnosis.
Gender Age Underlying Disease Immunosuppressant
Time Period from
Last Administration

















RTX mono 110 months Negative Negative 68 148 0.55 242 0.96










28 months Negative Negative 55 111 3.08 1010 1.21

















5 mg prednisolone mono
from 2015 on
73 months Negative Negative 26 32 0.88 368 1.17
Reference ranges: ALT < 35 U/L, AST < 35 U/L, Total bilirubin < 1.20 mg/dL, GGT 8–61 U/L; Abbreviations: ALT—alanine aminotransferase, AST—aspartate aminotransferase,
GGT—gamma glutamyl transferase, INR—international normalized ratio, R-CHOP—rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone.
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Figure 1 shows the clinical course of HEV infection in our five patients, depicting the HEV load
under the respective RBV treatment regimens and the development of HEV mutations associated
with RBV resistance determined by Sanger sequencing. As depicted in Table 3, patient #1 exhibited
hypogammaglobulinemia with decreased levels of IgG, IgA, and IgM. While expressing normal levels
of CD19+ cells, class-switched memory B cells (CD19+ IgD-IgM-CD27+) were clearly diminished (0.2%
of CD19+). In addition, patient #1 showed a profound T- and CD4-lymphopenia (190/µL absolute
counts) and a low percentage of naïve CD4+ cells. In patient #2, no CD19+ B cells were detectable
more than 12 months after the last RTX treatment. In agreement with the diagnosis of Waldenstrom’s
disease, IgM levels were increased, while levels of IgG and IgA were reduced. Expressing only a mild
T-lymphopenia, patient #2 also showed a relevant reduction in CD4+ cells (180/µL absolute cell count)
and low naïve CD4+ cells. Patient #3 exhibited lower IgG trough levels and a complete reduction of IgA
and IgM under immunoglobulin replacement therapy. No CD19+ B cells were detectable. Moreover,
patient #3 also showed CD4-lymphopenia (100/µL absolute cell count) with low naïve CD4 cells. Patient
#4 revealed hypogammaglobulinemia with reduced levels of IgG, IgA, and IgM with completely
diminished CD19+ cells. In addition, patient #4 showed profound T- and CD4-lymphopenia (180/µL
absolute counts) including a low percentage of naïve CD4+ cells (1%). According to his clinical files,
patient #5 had normal immunoglobulin levels after kidney transplantation and before the initiation of
PTLD chemotherapy. After chemotherapy the patient expressed constant hypogammaglobulinemia
with IgG levels as low as 0.75 g/L, IgA levels of 0.2 and no detectable IgM levels. Finally, patient #5 also
showed complete B-lymphopenia, NK-lymphopenia, and a severe T-lymphopenia with an absolute
CD4 count of 50/µL.
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Table 3. Immunological parameters of the patient cohort. 
 Patie t #1 Patient #2 Patient #3 Patie t #4 Patient #5 
IgG (7–16 g/L) 4.12 3.04 4.69 5.44 2.14 
IgA (0.7–4.00 g/L) 0.36 0.29 <0.1 0.36 0.18 
IgM (0.4–2.30 g/L) 0.07 12.46 <0.05 0.07 0.07 
Specific anti-pneumococcal-IgG (10–191.20 mg/L) 41.81 10.12 unknown 115.11 unknown 
CD19+ (0.1–0.4/nl) 0.18 0.00 0.00 0.00 0.00 
CD19+IgD+CD27- 
(42.6–82.3%) 
93.7 n.a. n.a. n.a. n.a. 
CD19+IgD+IgM+CD27+ 
(7.4–32.5%) 
3.8 .a. n.a. n.a. n.a. 
CD19+IgD-IgM-CD27+ 
6.5–29.1%) 
0.2 n.a. n.a. n.a. n.a. 
CD19+CD21lowC 38low 
(0.9–7.6%) 
0.6 n.a. n.a. n.a. n.a. 
CD19+CD21lowCD38++IgM+ 
(0.6–3.4%) 
1.3 n.a. n.a. n.a. n.a. 
CD19+CD21lowCD38++IgM- 
(0.4–3.6%) 
0.1 n.a. n.a. n.a. n.a. 
CD3+ (0.9–2.2/nl) 0.29 0.89 0.42 0.52 0.08 
CD3+CD4+ (0.5–1.2/nl) 0.19 0.18 0.1 0.18 0.05 
CD3+CD8+ (0.3–0.8/nl) 0.09 0.67 0.3 0.31 0.03 
CD3+CD4+CD45RA+ (>15%) 9 4 8 1 n.d. 
Abbreviations: n.a.—not assessable due to B-lymphopenia; n.d.—not determined. 
 
Figure 1. HEV load under ribavirin (RBV) treatment. 
  
Figure 1. HEV load under ribavirin (RBV) treatment.
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Table 3. Immunological parameters of the patient cohort.
Patient #1 Patient #2 Patient #3 Patient #4 Patient #5
IgG (7–16 g/L) 4.12 3.04 4.69 5.44 2.14
IgA (0.7–4.00 g/L) 0.36 0.29 <0.1 0.36 0.18
IgM (0.4–2.30 g/L) 0.07 12.46 <0.05 0.07 0.07
Specific anti-pneumococcal-IgG
(10–191.20 mg/L) 41.81 10.12 unknown 115.11 unknown
CD19+ (0.1–0.4/nl) 0.18 0.00 0.00 0.00 0.00
CD19+IgD+CD27-
(42.6–82.3%) 93.7 n.a. n.a. n.a. n.a.
CD19+IgD+IgM+CD27+
(7.4–32.5%) 3.8 n.a. n.a. n.a. n.a.
CD19+IgD-IgM-CD27+
(6.5–29.1%) 0.2 n.a. n.a. n.a. n.a.
CD19+CD21lowCD38low
(0.9–7.6%) 0.6 n.a. n.a. n.a. n.a.
CD19+CD21lowCD38++IgM+
(0.6–3.4%) 1.3 n.a. n.a. n.a. n.a.
CD19+CD21lowCD38++IgM-
(0.4–3.6%) 0.1 n.a. n.a. n.a. n.a.
CD3+ (0.9–2.2/nl) 0.29 0.89 0.42 0.52 0.08
CD3+CD4+ (0.5–1.2/nl) 0.19 0.18 0.1 0.18 0.05
CD3+CD8+ (0.3–0.8/nl) 0.09 0.67 0.3 0.31 0.03
CD3+CD4+CD45RA+ (>15%) 9 4 8 1 n.d.
Abbreviations: n.a.—not assessable due to B-lymphopenia; n.d.—not determined.
In summary, all patients exhibited relevant hypogammaglobulinemia and T-lymphopenia
following RTX-containing treatment regimens in the past.
HEV subgenotypes and potential RBV treatment failure-associated mutations are listed in Table 4.
Table 4. HEV subgenotypes and potential RBV treatment failure-associated mutations.
Patient #1 Patient #2 Patient #3 Patient #4 Patient #5
Sample used for analysis
(days after first positive PCR) 345 70 176 1 27
HEV subgenotype 3c 3c 3c 3 (could notbe assigned) 3c
Y1320H wt wt wt wt wt
K1383N mut wt mut wt wt
D1384G mut wt wt wt wt
K1398R wt wt wt wt wt
V1479I wt wt wt mut wt
Y1587F wt wt mut/wt wt wt
G1634R mut mut mut/wt wt wt
Abbreviations: wt—wild-type; mt—mutant. Amino acid numbering throughout the manuscript is according to
NCBI reference sequence NP_056779 as proposed by Debing et al. [20,21].
4. Discussion
Persistent HEV infections in immunocompromised patients following RTX-containing treatment
regimens have recently emerged [9]. Here we report the largest patient cohort with chronic hepatitis E
in this special risk population. In line with previous observations in RTX-treated patients [13,15,17],
none of our patients exhibited anti-HEV-IgM-antibodies. This observation adds further evidence to
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the obvious limitation of serological screening approaches as suggested by current HEV management
guidelines [2] and highlights the need for early molecular HEV screening and monitoring in RTX-treated
patients with persistently elevated aminotransferases. Moreover, the limited treatment response in our
cohort was in line with previous observations suggesting that persistent HEV infection in RTX-treated
patients might be difficult to treat by applying standard RBV treatment regimens, since only one of
our five patients achieved SVR. On a molecular level, treatment failure to RBV was accompanied by
the emergence of RBV treatment failure-associated HEV mutations in our patients (Table 4). These
mutations presumably interact in a complex manner resulting in RBV treatment failure. The G1634R
mutation is well described and appeared in our cohort in two patients who failed to achieve SVR
and in patient #2 who could only clear HEV after a second application of RBV. Another mutation
suspected to be relevant in the mechanism of RBV treatment failure is the K1383N mutation which
appeared in two patients in our case series that both experienced treatment failure. In addition,
other previously described RBV-treatment failure mutations occurred in our patient cohort without
a particular accumulation and some mutations previously described could not be detected in any
patient. Notably patient #5, who could only be treated with RBV for a very short period of time due to
his clinical condition, did not show any of the previously described mutations. Taken together, our
findings appear to add further evidence for the potential impact of HEV mutations on the outcome of
standard ribavirin therapy, which has been controversially discussed in the past [24,25].
Furthermore, there are a number of relevant observations in the present cohort which need to be
addressed. First, the time period between last administration of RTX and the establishment of chronic
HEV infection ranged up to 110 months in our cohort, which was considerably longer compared to
previous reports that described HEV persistence either while under ongoing RTX treatment or after a
maximum time period of 12 months following the last RTX application [15]. Second, Alnuaimi et al.
postulated that bendamustine might be the main risk factor in combination with RTX predisposing
for the acquisition of chronic hepatitis E [15]. However, our patients #1, #3, and #5 did not receive
bendamustine arguing against bendamustine as the main risk factor for HEV chronification. Third, we
analyzed the immunological characteristics of our cohort to unravel potential mechanisms underlying
RTX-induced HEV persistence, which revealed two major findings. All patients presented with a
relevant hypogammaglobulinemia, which required intravenous immunoglobulin replacement therapy
in two patients. A detailed analysis of B cell subsets showed severely reduced class-switched memory
B cells (CD19+IgD-IgM-CD27+) in one patient, while the absolute B-lymphopenia did not allow a
detailed quantification of B cell subsets in the other four patients. In addition, all patients showed
a relevant CD4-lymphopenia (all patients < 200/µL) with low levels of naïve CD4 cells (< 10% in all
patients). Of note, while hypogammaglobulinemia is an expected and known adverse event following
RTX treatment, it has been reported that RTX treatment can induce CD4-lymphopenia [26–28].
It remains to be determined whether the hypogammaglobulinemia, the CD4-lymphopenia or the
combination of both constitute the major risk factor for HEV persistence following RTX-containing
treatment regimens. There is only limited data on the prevalence of acute or chronic HEV infection
in patients with hypogammaglobulinemia. Mohamed et al. did not find HEV RNA in 27 patients
with primary antibody deficiency and persistently elevated liver enzymes [29]. In addition, increased
rates of acute or chronic HEV infection have not been observed in patients with relevant primary
antibody deficiency such as common variable immunodeficiency disorders (CVID) [30,31]. With
respect to a possible role of T-lymphocytes, particularly in HIV-positive patients, CD4-lymphopenia
was found to correlate with increased seroprevalence of anti HEV IgG [10]. A previous treatment
with RTX is possibly the common denominator for both observed immunological abnormalities. In
patients suffering from rheumatoid arthritis treated with RTX, a reduction of CD4-cells has been
described [24–26]. Although the long-term duration of CD4-lymphopenia following RTX therapy is not
known, RTX-related CD4-lymphopenia in our patients cannot be ruled out. However, due to missing
data prior to the onset of RTX treatment and prior to the detection of hepatitis E, we cannot exclude
that the observed CD4-lymphopenia resulted as a consequence of the infection rather than the previous
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RTX therapy or possibly already existed even before initiating RTX treatment. The elements of immune
response requirements for efficient HEV clearance remain poorly understood. Specific IgG-antibodies
to open reading frame (ORF) 1 and ORF2 and CD4+ and CD8+ effector memory T cells have been
associated with control of HEV infection and appear to play a central role in the development of long
lasting protection for re-infection with HEV [32,33]. The low CD4+ T-cell counts observed in our
cohort might therefore be associated with treatment failure. Of note, T cell-based immunotherapies
have recently been discussed as promising novel treatment approaches in chronic hepatitis E [34].
Current treatment guidelines recommend pre-therapeutic testing for hepatitis B virus prior to
the initiation of RTX-containing treatment regimens [18]. It remains to be determined whether these
recommendations should be extended to HEV testing. Our data do not allow to distinguish between a
potential HEV reactivation, which has been controversially discussed in the past [35,36], or de novo
infections e.g., by treatment-associated transfusions, which appear to represent a relevant risk for HEV
infection for immunosuppressed patients [37].
5. Conclusions
Considering the obvious risk of difficult-to-treat HEV persistence in HEV seropositive patients,
the administration of RTX should be considered carefully by attending physicians in case of alternate
effective treatment options. In addition, potential risk factors for HEV transmission such as consumption
of potentially contaminated meat products or blood product administration should be counselled
carefully in these patients. In the case of suspected hepatitis, molecular HEV testing appears to be
mandatory. In summary, here we report further evidence to prior anecdotal observations suggesting
that RTX-containing treatment regimens may imply a long-term increased risk for difficult-to-treat
chronic hepatitis E.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/17/1/341/s1.
Table S1: Reported cases of hepatitis E after administration of RTX.
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